

EXPRESSION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE-2 IN DE NOVO AML PATIENTS: CLINICAL SIGNIFICANCE AND FUTURE PROSPECTS

THEISIS

Submitted for partial fulfillment of the M. D degree in clinical and chemical pathology

BY

Engy Mohammed Abd El Aziz El Khatib

M. B. B. Ch. M. Sc

Supervisors

Prof. Dr./Safaa Mostafa El Karaksy

Professor of Clinical and Chemical Pathology

Faculty of Medicine

Cairo University

Dr./Nancy Mohammed El Guindy

Assistant Professor of Clinical Pathology

Faculty of Medicine

Cairo University

Dr./Heba Mahmoud Gouda

Lecturer of Clinical Pathology

Faculty of Medicine

Cairo University

Dr./Noha Yehia Abdou Ibrahim

Lecturer of Clinical Oncology

Faculty of Medicine

Cairo University

Faculty Of Medicine

Cairo University

2009

التعبير عن انجيوبويتين ١ و ٢ ومستقبلهما تاي ٢ في حالات سرطان الدم الميلودي
الحاد حديثة التشخيص: الأهمية الاكلينيكية و التوقعات المستقبلية

رسالة مقدمة من :

الطبيبة/إنجي محمد عبد العزيز الخطيب

توطئة للحصول على درجة الدكتوراه فى الباثولوجيا الاكلينيكية و الكيميائية

تحت إشراف

أ.د/صفاء مصطفى القراقصي

أستاذ الباثولوجيا الاكلينيكية و الكيميائية
كلية الطب - جامعة القاهرة

أ.م/نانسي محمد الجندي

أستاذ مساعد الباثولوجيا الاكلينيكية
كلية الطب - جامعة القاهرة

د/هبة محمود جوده

مدرس الباثولوجيا الاكلينيكية

كلية الطب - جامعة القاهرة

د/نهى يحيى عبده ابراهيم

مدرس علاج الأورام

كلية الطب - جامعة القاهرة

كلية الطب

جامعة القاهرة

٢٠٠٩

بسم الله الرحمن الرحيم

((و علمك ما لم تكن تعلم و كان فضل الله عليك عظيما))

صدق الله العظيم

النساء ()

To my great father

To my great mother

To my special husband

To my precious brothers and sister

To my sweet kids

Acknowledgment

First and foremost thanks to Allah the most beneficial and merciful.

I would like to express my deepest gratitude and cordial thanks to Prof. Dr./ Safaa El Karaksy, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University. I am greatly thankful for her kind guidance, continuous support, precious advice and valuable help.

My sincere appreciation and special thanks are due to Prof. Dr./Nancy El Guindy, Assistant Prof. of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her kind supervision, continuous encouragement and generous cooperation.

I feel greatly indebted to Dr./Heba Gouda, Dr./Mervat Khorshed, Dr./Iman Abdel Mohsen, Dr./Reham Emad , Lecturers of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University and Dr./Noha Yehia, Lecturer of Clinical Oncology, Faculty of Medicine, Cairo University, for their close supervision, indispensable direction and for the time they freely gave for guiding me.

Last but not least, I would like to express my sincere thanks to my friends and colleagues for their support and continuous encouragement during preparation of this work.

LIST OF CONTENTS

Acknowledgment.

Dedication.

Abstract.....	I
List of abbreviations.....	II
List of figures.....	VI
List of tables.....	VII
Introduction and aim of the work.....	1
Chapter I (Acute myeloid leukemia).....	5
Chapter II (Angiogenesis).....	39
Chapter III (Angiopoietins).....	62
Participants & methods.....	76
Results.....	92
Discussion.....	107
Summary	114
References.....	117
Arabic summary.....	١

List of Abbreviations

ABL	: Abelson strain of murine leukemia virus
AKT	: Protein kinase B, a serine /threonine specific enzyme known as AKT.
ALL	: Acute lymphoblastic leukemia.
AMbL	: Acute myeloblastic leukemia
AMgL	: Acute megakaryocytic leukemia
AML	: Acute myeloid leukemia.
AMML	: Acute myelomonocytic leukemia.
AMoL	: Acute monocytic leukemia
ANAE	: Alpha naphthol acetate esterase.
Ang-1	: Angiopoietin 1.
Ang-2	: Angiopoietin 2.
Angs	: Angiopoietins.
ANLL	: Acute non-lymphoblastic leukemia.
APL	: Acute promyelocytic leukemia.
ATRA	: all-transretinoic acid.
BCR	: Break point cluster region
BM	: Bone marrow.
CBF	: Core binding factor.
CBF/A	: Core binding factor alpha subunit.
CBF/β	: Core binding factor beta subunit.
CEPBA	: CCAAT/enhancer binding protein –α.
CML	: Chronic myeloid leukemia .
CMML	: Chronic myelomonocytic leukemia.
CR	: Complete remission.
DFS	: Disease free survival
DIC	: Disseminated intravascular coagulation .
DLL4	: Delta-like ligand 4.
DNA	: Deoxyribonucleic acid.
ECM	: Extracellular matrix.
EGF	: Eosinophil growth factor.
EM	: Electron microscope.
ETO	: Eight Twenty one.
FAB	: French American British classification.
FGF	: Fibroblast growth factor.
FISH	: Fluorescence in situ hybridization .

FLT3	: FMS-like tyrosine kinase-3
G-CSF	: Granulocyte colony stimulating factor.
GM-CSF	: Granulocyte-monocyte colony stimulating factor.
HGFs	: Hematopoietic growth factors.
HLA-DR	: Human leucocyte antigen DR locus.
ICAM-1	: Intracellular adhesion molecule-1.
IL	: Interleukin.
LM	: Light microscope.
M-CSF	: Monocyte colony stimulating factor.
MDS	: Myelodysplastic syndrome.
MLL	: Mixed lineage leukemia
MLLT3	: Mixed lineage leukemia translocated to,3
MMP	: Matrix metalloproteinase.
MPD	:Myeloproliferative disorder.
MPO	: Myeloperoxidase.
MRD	: Minimal residual disease.
NEC	: Non-erythroid cell.
NO	: Nitric oxide.
NOS	:Not otherwise specified
NSE	: Non-Specific esterase.
OS	: Overall survival.
PAS	: Periodic acid Schiff.
PB	: Pripheral blood.
PDGF	: Platelet derived growth factor.
PECAM-1	:Periendothelial cell adhesion molecule-1.
PKG	: cGMP-dependent protein kinase.
PML-RARA	: Promyelocytic leukemia-Retinoic acid receptor alpha.
PTD-MLL	: Partial tandem duplication-Mixed lineage leukemia.
Rb	: Retinoblastoma gene.
RT-PCR	: Reverse transcriptase polymerase chain reaction.
SBB	: Sudan black B.
SCF	: Stem cell factor.
SPECT	: Single photon emission computed tomography.
TCR	: T cell receptor.
Tdt	: Terminal deoxy nucleotydydyl transferase
TLC	: Total leucocytic count.
UAL	: Undifferentiated acute leukemia.
US	: United states.
VCAM-1	: Vascular cell adhesion molecule-1.
VEGF	: Vascular endothelial growth factor.

WHO	: World Health Organization.
WT-1	: Wilm's tumor 1 gene.

List of Figures

Figure 1: Peripheral blood of an AML patient M0 FAB subtype -----	P.11
Figure 2: Bone marrow of an AML patient M1 FAB subtype -----	P.11
Figure 3: Bone marrow of an AML patient M2 FAB subtype -----	P.12
Figure 4: Bone marrow of an AML patient M3 FAB subtype -----	P.12
Figure 5: Peripheral blood of an AML patient M3 variant FAB subtype	P.13
Figure 6: Bone marrow of an AML patient M4 FAB subtype -----	P.13
Figure 7: Bone marrow of an AML patient M4eo FAB subtype -----	P.14
Figure 8: Peripheral blood of an AML patient M5a FAB subtype ----	P.14
Figure 9: Bone marrow of an AML patient M5b FAB subtype -----	P.15
Figure 10: Bone marrow of an AML patient M6 FAB subtype -----	P.15
Figure 11: Peripheral blood of an AML patient M7 FAB subtype ----	P.16
Figure 12: Sudan black B staining -----	P.17
Figure 13: Sudan black B stain. -----	P.17
Figure 14: Alpha Naphthol acetate esterase (non-specific esterase) staining -----	P.18
Figure 15: Chloroacetate (specific estrase) staining -----	P.18
Figure 16: Dual estrase staining -----	P.19
Figure 17: PAS staining-----	P.19
Figure 18: Flow chart how individual patients are categorized in the WHO classification -----	P.24
Figure 19: Physiological angiogenesis-----	P.42
Figure 20: Improvement in myocardial perfusion after FGF-1 treatment as demonstrated by SPECT imaging -----	P.60
Figure 21: Structural organization of Angs family -----	P.65

Figure 22: Structural organization of Ang-binding receptors -----	P.66
Figure 23: Model of the overall structures of Tie1 and Tie2 receptors	P.70
Figure 24: Tie-2 dependent and Tie-2 independent signaling of Angs in endothelial and nonendothelial cells. -----	P.72
Figure 25: Angiogenic cycle of vascular developments -----	P.74
Figure (26): The response to induction chemotherapy-----	P.95
Figure (27): Expression of Ang-1, Ang-2 and, Tie-2 in AML patients	P.97
Figure (28): Expression of Ang-1, Ang-2 and, Tie-2 in control group	P.98
Figure (29): Statistical comparison between AML patients and control group as regards Ang-1, Ang-2 and Tie-2-----	P.99

List of Tables

Table (1): Conditions predisposing to the development of acute myeloid leukemia.-----	P.6
Table (2): Morphologic (FAB) classification of AML.-----	P.10
Table (3): Immunophenotypic markers in AML.-----	P.21
Table (4): The WHO classification of AML.-----	P.22
Table (5): The WHO classification “AML not otherwise categorized”--	P.23
Table (6): Recent WHO classification -----	P.28
Table (7): Chemical stimulators of angiogenesis -----	P.43
Table (8): Endogenous inhibitors of angiogenesis-----	P.56
Table (9): The reagents used for RT-PCR-----	P.83
Table (10): Ang-2, Ang-1,Tie-2 and β -Actin specific primers sequence	P.84
Table (11): The reaction components for master mix 1-----	P.86
Table (12): The reaction components for master mix 2-----	P.87
Table (13): Thermo-cycler programs used to amplify the studied genes	P.87
Table (14): Clinical characteristics of the AML patients-----	P.93
Table (15): Laboratory Characteristics of the Patients-----	P.94
Table (16): The response to induction chemotherapy-----	P.95
Table (17): Expression of Ang-1, Ang-2 and, Tie-2 in AML patients---	P.96
Table (18): Expression of Ang-1, Ang-2 and, Tie-2 in control group---	P.98
Table (19): Statistical comparison between AML patients and control group as regards Ang-1, Ang-2 and Tie-2-----	P.99

Table (20): Descriptive and comparative data of the three groups of AML patients-----P.104

Table (21): Individual data of the control group-----P.106

Abstract

Angiopoietins are a group of the most potent and specific positive regulators involved in angiogenesis. The activity of angiopoietins is mediated by interaction with high affinity receptor tyrosine kinase (RTKs), expressed on most endothelial cells, which is Tie-2 receptor.

Angiopoietins and their receptor may play a very important role not only in angiogenesis but also in leukemogenesis. Their expression on leukemic cells may elucidate their role as autocrine promoters of malignant cell proliferation in acute myeloblastic leukemia and in other hematologic malignancies as they trigger proliferation, survival and migration of malignant hematopoietic cells. Their expression may have clinical relevance and important role as risk and prognostic factors in acute leukemia. They may be useful as predictive test for treatment outcome in acute leukemia patients.

Key Words:

Angiopoietin, Tie2, Acute leukemia

Introduction

Leukemias are complex diseases with a wide range of clinical, morphologic, biologic, cytogenetic, molecular and immunophenotypic features (**Estey, 2001**). With this multitude of disease-associated variables, it is not surprising that response to treatment differs considerably among patients (**Bennett, 2000**).

A major component in the growth and metastasis of solid tumors is angiogenesis which is defined as the formation of new blood vessels. However, angiogenesis has been found to play a role in hematologic malignancies (**Di Raimondo et al., 2001**).

The process of angiogenesis is governed by a complex balance of positive and negative regulatory factors. Stimulatory molecules include VEGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), tumor necrosis factor- α , tumor growth factor- β , angiogenin, epidermal growth factor and the angiopoietins (**Folkman, 1995**). Of the most potent positive regulatory molecules are Ang-1 and Ang-2, which may act synergistically to stimulate the formation of new blood vessels. Negative regulatory factors include platelet factor-4, thrombospondin-1, tissue inhibitors of metalloproteinases, prolactin, angiostatin, endostatin, bFGF soluble receptor, interferon- α and placental proliferin-related protein. Increased levels of positive regulatory molecules have been correlated with a poor prognosis in patients with solid tumors (**Ugurel et al., 2001**). Studies of human hematopoietic cell lines have demonstrated the presence of either Ang-1 mRNA or Ang-2 mRNA, or both in all cell lines examined (**Bellamy et al., 1999**).